Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
20 22 Search
2024
Genome-wide association identifies novel ROP risk loci in a multiethnic cohort
Communications Biology
2023
The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression
Frontiers in Pharmacology
2023
The current landscape of m6A modification in urological cancers
PeerJ
2022
The risk of COVID-19 can be predicted by a nomogram based on m6A-related genes
Infection, Genetics and Evolution
2022
Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte‐associated genes
Cancer Medicine
2022
Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer
Pathology and Oncology Research
2021
A Ten-N6-Methyladenosine (m6A)-Modified Gene Signature Based on a Risk Score System Predicts Patient Prognosis in Rectum Adenocarcinoma
Frontiers in Oncology
2021
Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases
Frontiers in Oncology
2021
RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
Frontiers in Oncology
2021
Identification of a Two‐m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis
BioMed Research International
2021
Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro
Frontiers in Oncology
2021
A Risk Score Model Incorporating Three m6A RNA Methylation Regulators and a Related Network of miRNAs-m6A Regulators-m6A Target Genes to Predict the Prognosis of Patients With Ovarian Cancer
Frontiers in Cell and Developmental Biology
2021
Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
Bioengineered
2021
N6‐Methyladenosine (m6A) readers are dysregulated in renal cell carcinoma
Molecular Carcinogenesis
2020
N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives
Biochemical Pharmacology
2020
The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer
Future Oncology
2020
The Potential Roles of RNA N6-Methyladenosine in Urological Tumors
Frontiers in Cell and Developmental Biology
2020
m6A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1
Frontiers in Oncology
2020
Exploring diagnostic m6A regulators in endometriosis
Aging
2020
A Three-Metabolic-Genes Risk Score Model Predicts Overall Survival in Clear Cell Renal Cell Carcinoma Patients
Frontiers in Oncology
Additional cited-by details will be shown when available from Crossref